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Treatment strategies for inflammatory bowel disease (IBD) focus on the induction and long-
term maintenance of deep remission to avoid complications of active disease and improve long-
term outcomes. Medical therapies for IBD, notably the increasingly widespread use of biological 
therapy, are often effective at controlling disease, but these drugs are associated with substantial 
adverse events, which together with other factors—including increasing treatment costs and 
patient preferences—leads to concerns regarding indefinite use of medical therapy. 
Consequently, the need to consider the safety and feasibility of drug de-escalation once IBD 
remission has been achieved is clear. Here, we review the current evidence surrounding de-
escalation of immunomodulator and biological therapy in Crohn’s disease and ulcerative colitis. 
We discuss strategies for de-escalation, including the selection of patients who are appropriate 
for treatment de-escalation and the use of proactive drug monitoring, and review the evidence 
on subsequent optimal follow-up. We conclude by proposing an algorithm to guide de-escalation 
decisions, and highlight future perspectives, including the potential effect of emerging 
medication and personalised medicine for these diseases. 
Introduction 
Therapeutic strategies for inflammatory bowel disease (IBD) have substantially changed over 
the past decade, with widespread acknowledgment that deep remission (defined as clinical, 
biochemical, and endoscopic remission) is associated with better long-term outcomes.1 
Consequently, patients are increasingly treated with biological agents, immunomodulators, or 
both, in early stages of disease. Two key studies support this approach: CALM2 and REACT.3 The 
CALM study showed the benefits of prompt escalation with anti-TNF therapy in patients with 
early Crohn’s disease, with a higher proportion of those assigned to tighter disease control 
achieving mucosal healing and clinical remission.2 In the REACT study, patients with Crohn’s 
disease who received accelerated combination therapy with anti-TNF and antimetabolite drugs 
had a lower prevalence of major adverse outcomes, including surgery, hospital admission, and 
serious disease- related complications, than those receiving conventional therapy; however, 
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these adverse outcomes were secondary endpoints, and no difference was noted in the primary 
endpoint of steroid-free remission.3 
Aggressive escalation of medical therapy early in the disease course appears to improve disease 
control, but once remission has been achieved both clinicians and patients face challenging 
questions about the timing and feasibility of treatment de-escalation. In this Review, we address 
the elective discontinuation of immunomodulator and biological therapy for patients who have 
achieved sustained clinical remission. The issues surrounding discontinuation of therapy for 
other reasons, including pregnancy, planned surgery, and intercurrent infection or malignancy, 
are addressed comprehensively elsewhere.4-8 
Undoubtedly, the safety of immunomodulators and biological therapy is a key issue for 
clinicians, but the risk of drug-related adverse events must be balanced against the harmful 
effects of losing disease control.9 
Particular concern has surrounded the risk of infectious complications and drug-related 
lymphoproliferative dis-orders. Registry data have confirmed the risks of monotherapy and have 
highlighted that patients on combination therapy are at greatest risk.10,11 Withdrawal of a 
thiopurine drug reduces the risk of lymphoproliferative disorders, with a prospective study 
showing a lower incidence of such adverse events in patients with IBD who discontinued 
thiopurine treatment (0.20 per 1000 patient-years) and those who were never exposed to 
thiopurine (0.26 per 1000 patient-years) compared with those who continued thiopurine 
treatment (0.90 per 1000 patient-years; p=0.0054).12 Taken together, these data suggest that 
de-escalation of drug therapy, in particular combination therapy, might reduce the risk of 
serious drug-related adverse events. 
De-escalation of therapy also provides cost savings, an important consideration at a time of 
increasing pressure on health-care budgets worldwide. The COIN study13 from the Netherlands 
showed that IBD healthcare costs are predominantly driven by the cost of medication, in 
particular anti-TNF therapy, which accounted for 64% of the total cost in Crohn’s disease and 
31% of the total cost in ulcerative colitis. Data from the TAXIT trial14 showed that de-escalation 
of infliximab dosing, based on trough concentrations, led to a 28% reduction in drug costs both 
for patients with Crohn’s disease and those with ulcerative colitis who had initially shown a full 
or partial response to infliximab maintenance therapy, without impairing clinical outcome. 
However, both studies13,14 predate the arrival of biosimilars, which have provided significant 
cost savings. The cost-effectiveness of de-escalation versus non-de-escalation, based on 
infliximab trough concentrations, has been compared in virtual cohorts of patients with Crohn’s 
disease in remission.15 Over the modelled 2-year follow-up period, infliximab de-escalation, 
based on trough concentrations, was predicted to lead to a cost saving of 6.1%, corresponding to 
€25.4 million per 10 000 patients. The use of infliximab biosimilars resulted in a lower, but still 
substantial, absolute cost saving of €13.8 million per 10000 patients.15 
In this Review, we discuss the best available evidence on de-escalation of immunomodulators 
and biological therapy for patients with IBD in remission, considering these treatments both 
separately and in combination. We propose an algorithm to guide de-escalation decisions and 
conclude by highlighting noteworthy future perspectives, including the potential effect of 
personalised medicine and emerging therapies. 
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Withdrawal of immunomodulator monotherapy 
Four randomised controlled trials (RCTs) have evaluated the withdrawal of immunomodulator 
monotherapy in patients with Crohn’s disease in clinical remission.16-18,20 All of the studies 
reported higher relapse in the withdrawal groups.30 In a multicentre, double-blind, non--
inferiority withdrawal study, patients with Crohn’s disease in clinical remission on azathioprine 
for at least 42 months were randomly assigned to either continue azathioprine or receive a 
placebo. The relapse rate was higher in the placebo group than in the azathioprine group (nine 
[21%] of 43 patients vs three [8%] of 40) at 18 months. The authors concluded that withdrawal 
of azathioprine was not equivalent to continuation with regard to maintenance of remission; as a 
result, azathioprine maintenance therapy should be continued beyond 3.5 years of treatment.17 
A follow-up of this study, which was limited by the small number of patients recruited (n=66), 
showed that the cumulative probability of relapse was 52.8% (SE 7.1) at 3 years and reached 
62.7% (7.2) at 5 years. Thus, azathioprine withdrawal was associated with a high-risk of relapse 
even after a long period of clinical remission.31 In a second study, 52 patients with Crohn’s 
disease who has been treated with azathioprine for at least 48 months were randomly assigned 
to either continue azathioprine or switch to placebo. The proportion of patients in remission 
after 1 year of follow-up was lower in the placebo group (76% [SD 8]) than in the azathioprine 
group (96% [4]) p=0.035, but this statistically significant difference was lost after 2 years.16 A 
Cochrane meta-analysis based on data from four studies with follow-up between 12 and 24 
months indicated that overall, 36 (32%) of 111 patients relapsed following azathioprine 
withdrawal in comparison with 14 (13%) of 104 patients who relapsed after continuing 
azathioprine therapy (relative risk 0.42 [95% CI 0.4-0.72]; p=0.002).32 Retrospective studies 
have reported higher relapse rates following the withdrawal of immunomodulators; 14-38% at 
12 months, 39-71% at 24 months, 53-85% at 36 months, and 63-85% at 60 months.30 None of 
these studies assessed azathioprine metabolite concentrations, which might prove to be 
important in predicting relapse following de-escalation of thiopurine monotherapy. 
A small RCT involving patients with ulcerative colitis reported a relapse rate of 61% (17/28) for 
patients in long term remission when azathioprine was withdrawn versus 31% (8/26) in those 
continuing their azathioprine regimen (p<0.001) by the end of the first year of followup.19 
Importantly, patients who had taken azathioprine for 6 months before de-escalation were 
included, which might explain the high relapse rates. Longer follow-up times have been assessed 
in retrospective cohort studies. Relapse rates ranged from 43-65% at 5 years to 75-87% over 
longer periods.30 Finally, a retrospective study of 70 patients with IBD (48 patients with Crohn’s 
disease and 22 with ulcerative colitis) evaluated relapse rate after methotrexate withdrawal. 
The probability of remaining in remission was higher when methotrexate was continued (90%) 
than if discontinued (21%) after 12 months of follow-up, with no difference found between 
patients with Crohn’s disease and those with ulcerative colitis.33 We have summarised the RCTs 
of immunomodulator withdrawal in table 1. 
In summary, withdrawal of immunomodulator monotherapy (thiopurine or methotrexate) is 
associated with a substantial risk of relapse both in patients with Crohn’s disease and those with 
ulcerative colitis, even among patients who have achieved long-term remission. These data need 
to be weighed against the evidence for the cumulative increased risk of serious complications 
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with long-term therapy and the suggestion that a period off therapy will significantly reduce the 
risk of drug-related lymphoma.12 
Withdrawal of the immunomodulator from combination 
therapy 
In an open-label RCT,28 patients with Crohn’s disease receiving combination therapy with 
immunomodulators and infliximab for at least 6 months were randomly assigned to either 
continue or stop immunomodulators. No difference in the primary endpoint, the proportion of 
patients who required a decrease in infliximab dosing interval or cessation of infliximab due to 
the loss of response or clinical relapse, was found between the two groups over a 24-month 
period of follow-up (24 [60%] of 50 patients who continued immunomodulator vs 22 [55%] of 
40 patients who discontinued immunomodulator), suggesting that the continuation of 
immunomodulators was not superior to withdrawal. Endoscopic healing, defined by the absence 
of mucosal ulcers, was also similar in both groups (16 [64%] of 25 in the continuation group vs 
14 [61%] of 23 in the discontinuation group), although combination therapy was associated 
with lower concentrations of C-reactive protein (CRP).29 A further open-label RCT, DIAMOND2,34 
assessed thiopurine withdrawal from the treatment regimen of patients in steroid-free clinical 
remission for at least 6 months following combination therapy with adalimumab. Preliminary 
results report no difference in the primary endpoint of steroid-free remission at 52 weeks, or in 
a secondary endpoint of mucosal healing, suggesting no clear benefit in continuation of 
immunomodulators beyond 6 months of clinical remission. However, only a small number of 
patients (n=50) were included, and the thiopurine dose was much lower than that commonly 
used in Europe.34 
A subsequent systematic review has analysed relapse rates following immunomodulator 
(azathioprine) discontinuation from combination therapy in Crohn’s disease. Overall, 27 (49%) 
of 55 patients relapsed after immunomodulator withdrawal compared with 27 (48%) of the 56 
patients who continued immunomodulators (RR 1.02 [0.68-1.52]; p=0.92). However, the quality 
of data was considered low because of high risk of bias for study blinding and small patient 
numbers;32 nevertheless, retrospective cohort studies have also suggested no difference in 
clinical outcome.26,30 One observational study reported a cumulative relapse rate of 27% at a 
median follow-up of 14 months,27 and a second reported 38% at 29 months.25 The probability of 
relapse appears to increase substantially over time, with a third study reporting a relapse rate of 
72-.% at a median follow-up of 61.6 months.20 Finally, in a paediatric population no difference in 
relapse was found between those randomly assigned to either continue (33.3%) or discontinue 
immunomodulators (35.9%).23 
Only a small amount of data exists regarding the relapse of patients with ulcerative colitis 
following immunomodulator discontinuation, but a large retrospective study reported a lower 
prevalence of relapse among patients who continued on combination therapy (12 [3%] of 392) 
than among those receiving infliximab alone (33 [12%] of 282; p=0-049).24 Studies investigating 
immunomodulator withdrawal from combination therapy are summarised in table 2. 
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In summary, withdrawal of immunomodulators from combination therapy in Crohn’s disease 
does not appear to increase relapse rate at up to 2 years of follow-up. However, longer 
prospective studies are required for both Crohn’s disease and ulcerative colitis. 
The effect of immunomodulators withdrawal on the 
immunogenicity of biological therapy 
When considering the withdrawal of immunomodulators from combination therapy, the 
increased risk of biological immunogenicity must be acknowledged. The development of anti-
drug antibodies is of greatest concern in patients given anti-TNF therapy, with the prospective 
PANTS study35 reporting overall rates of antibody formation, with associated undetectable drug 
concentrations at week 54, to be 31.2% with infliximab and 12.3% with adalimumab.35 
Conversely, the gut selective α4β7 integrin antibody vedolizumab, and the interleukin 12/23 
p40 subunit antibody ustekinumab, are associated with much lower rates of antibody formation 
(1-4.1% for vedolizumab and 0.4-2.9% for ustekinumab).36 In anti-TNF therapy, the 
development of anti-drug antibodies is strongly associated with lower trough concentrations, 
loss of response, and infusion reactions.37,38 
Several studies have suggested immunomodulator continuation is associated with improved 
infliximab pharmacokinetics. Initial prospective work reported higher infliximab trough 
concentrations in patients who continued immunomodulator therapy.28 This association was 
confirmed in an RCT that found low or undetectable infliximab concentrations, with or without 
anti-drug antibodies, in 14.3% of those who continued azathioprine at a dose of 2-2.5 mg/kg per 
day, 14.8% of patients who continued with a halved azathioprine dose, and 43.3% of patients 
who stopped azathioprine.20 Maintaining concentrations of the azathioprine metabolite 6-TGN at 
more than 105 pmol/8 x 108 red blood cells was suggested to prevent low infliximab trough 
concentrations. A separate cross-sectional study found that 6-TGN concentrations correlated 
with those of infliximab, and patients with lower 6-TGN concentrations (<125 pmol/8 x108 red 
blood cells) were more likely to have antibodies to infliximab (odds ratio [OR] 13, 95% CI 2.3-
72.5; p<0.01).39 A further study reported that combination therapy resulted in a longer drug 
antibody free survival.40 The effect of immunomodulators on adalimumab trough concentrations 
is less clear, with the DIAMOND2 study34 reporting no difference at week 52 when the 
immunomodulator was discontinued after at least 6 months of combination therapy. Finally, 
results from the PANTS study35 have shown that concurrent immunomodulator use reduces the 
risk of immunogenicity for both infliximab (hazard ratio [HR] 0.39; p<0.0001) and adalimumab 
(HR 0.44; p<0.0001). As expected, immunogenicity was strongly associated with non-
remission.35 
The concept of optimised monotherapy, based on proactive therapeutic drug monitoring for 
anti-TNF drugs, has emerged as an alternative to combination therapy. In a retrospective study 
of 149 patients with IBD (94 patients with Crohn’s disease and 55 with ulcerative colitis), the 
less favourable pharmacokinetic profile initially observed with infliximab monotherapy could be 
overcome with dose escalation based on close therapeutic drug monitoring, with no difference 
in infliximab discontinuation, mucosal healing, hospitalisation, or long-term steroid use over a 
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median follow-up of 19 months.41 Concordant results were reported in a second retrospective 
study, in which early infliximab dose escalation resulted in similar clinical outcomes and 
infliximab trough concentrations regardless of concurrent immuno- modulator.42 
Taken together, although these data highlight the potential negative effect of immunomodulator 
withdrawal on anti-TNF pharmacokinetics and immunogenicity, an increased risk of relapse has 
not been shown, and proactive therapeutic drug monitoring emerges as a strategy to maintain 
anti-TNF efficacy. 
Withdrawal of anti-TNF therapy 
A number of studies over the past few years have focused on anti-TNF withdrawal both in 
patients with Crohn’s disease and those with ulcerative colitis.43-47 Overall, most studies report a 
relapse rate of 40-50% over a 2-year period following discontinuation of the anti-TNF drug, but 
treatment with concurrent immunomodulators varies greatly between the studies.30,48 The 
STORI49 trial remains the only prospective study designed to assess prevalence of relapse after 
anti-TNF withdrawal, but it did not have a control group. The trial enrolled patients with Crohn’s 
disease who had been treated for at least 1 year with infliximab and an antimetabolite, with 
steroid-free remission for a minimum of 6 months. The relapse rate was 43.9% (SE 5.0) at 12 
months and 52.2% (SE 5.2) at 24 months.49 Long-term outcomes, with a median follow-up of 7 
years, have been published, with only 21.6% of patients remaining in remission, while 71% 
restarted biological therapy after a median of 13 months. Of the 64 patients who restarted 
biological treatment, 22 were treated unsuccessfully with infliximab, either as a result of major 
complications (4/22) or secondary loss of response to infliximab (18/22) after a median time of 
22 months. The cumulative incidence of unsuccessful infliximab treatment was 30.1% (95% CI 
18.5-42.5) 6 years after infliximab restart.50 Importantly, major complications occurred 
relatively late after infliximab withdrawal (median 45 months), including 14 surgeries and four 
complex perianal lesions, emphasising the importance of close long-term monitoring following 
de-escalation. 
A retrospective cohort study compared the disease course of ulcerative colitis in clinical 
remission for at least 12 months in patients who continued or discontinued infliximab. Patients 
who discontinued infliximab had a higher probability of relapse (HR 3.41 [95% CI 1.88-6.20]; 
p<0.001). A separate study reported the relapse rate in patients with ulcerative colitis to be 
60% after 4.5 years of follow-up.43 
A multicentre retrospective study assessed the risk of relapse both for patients with Crohn’s 
disease and those with ulcerative colitis who discontinued anti-TNF after achieving clinical 
remission, with a median follow-up of 19 months.51 The cumulative incidence of relapse was 
44% per patient-year, with no significant difference between patients with Crohn’s disease and 
those with ulcerative colitis.51 A large retrospective cohort study from the UK reported relapse 
after anti-TNF withdrawal in patients with Crohn’s disease, ulcerative colitis, or IBD 
unclassified.46 Relapse rates were 36% at 1 year and 56% at 2 years of follow-up in patients with 
Crohn’s disease compared with 42% at 1 year and 47% at 2 years in those with ulcerative colitis 
or IBD unclassified. The authors also did a meta-analysis, which supported their findings.46 The 
Published in : The lancet. Gastroenterology & Hepatology (2020) 
DOI: 10.1016/S2468-1253(19)30186-4 




relapse rate at 1 year was 39% (95% CI 35-44) and 54% (49-59) at 2 years for patients with 
Crohn’s disease, whereas the relapse rate for patients with ulcerative colitis or IBD unclassified 
was 35% (26-43) at 1 year and 42% (27-58) at 2 years.46 A separate systematic review and 
meta-analysis produced similar results, with the overall risk of relapse after anti-TNF 
discontinuation being 44% in patients with Crohn’s disease and 38% in those with ulcerative 
colitis.57 We have summarised the largest studies evaluating de-escalation from anti-TNF (table 
3). 
An important and feared consequence of relapse following biological withdrawal in ulcerative 
colitis is colectomy. A prospective observational study reported outcomes following infliximab 
discontinuation in 51 patients in clinical remission: 18 (35%) patients needed to restart 
biological therapy, with only one patient not responding and requiring colectomy.54 Similarly, a 
separate study found that only one of 48 patients required colectomy following the withdrawal 
of infliximab.46 Additionally, a retrospective multinational cohort study of 193 patients found no 
differences in the frequency of colectomy between those who had discontinued infliximab and 
those who had continued on it.58 To the best of our knowledge, no studies have evaluated the 
clinical outcomes after stopping other biological agents, such as vedolizumab. 
Strategies for de-escalation of therapy in IBD: a review of 
the current evidence 
Although the long-term probability of maintaining remission following de-escalation of therapy 
appears disappointingly low, a number of strategies have been proposed to minimise the risk of 
a clinically significant relapse. 
STRATEGY ONE: THE SELECTION OF SUITABLE CANDIDATES FOR DE-
ESCALATION 
The identification of subgroups of patients who are at considerably lower risk of relapse 
following drug withdrawal might be possible. A number of studies have reported predictive 
factors for relapse, including a comprehensive systematic review that determined that the 
majority of predictive factors reflect known poor prognostic features, previous challenging 
disease course, and markers of active disease.30 However, no predictive factors for relapse have 
been consistently reproduced in ulcerative colitis, making stratification difficult in this cohort. 
Both demographics and clinical history must be considered when contemplating de-escalation. 
Young age at diagnosis and male sex are poor prognostic features for both ulcerative colitis and 
Crohn’s disease.30 However, of note, men younger than 35 years are at greatest risk of 
hepatosplenic T-cell lymphoma following more than 2 years of thiopurine therapy with or 
without anti-TNF, which although rare, carries a poor prognosis, underlining the challenges of 
decision making.59 Conversely, the risks of both infection and malignancy increase with 
thiopurine and anti-TNF treatment if the patient is older than 65 years, favouring 
discontinuation in older patients.10 Extensive disease is an important risk factor for Crohn’s 
disease, which has also been proposed for ulcerative colitis; additional adverse clinical features 
Published in : The lancet. Gastroenterology & Hepatology (2020) 
DOI: 10.1016/S2468-1253(19)30186-4 




of Crohn’s disease include smoking, perianal or colonic disease, and stricturing disease.30,47,51,55,60 
Discontinuation of biological therapy in perianal disease is associated with particularly high 
relapse rates, and continuation of therapy is strongly favoured in this group.61,62 Treatment 
history is also important, with a previous need for surgery, unsuccessful immunomodulator 
therapy, or relapsing course requiring escalation of therapy associated with higher risk of 
relapse.30,51 
The consequences of disease progression must also be assessed as part of the decision-making 
process. For example, one might decide not to de-escalate in a patient considered at low risk of 
relapse who has had multiple previous bowel resections, because any disease recurrence would 
place them at high risk of short bowel syndrome. 
Important laboratory markers of active disease that predict failure of de-escalation in Crohn’s 
disease include elevated CRP and neutrophil or white cell count, low haemoglobin, and elevated 
faecal calprotectin.49,55 Subtle abnormalities might confer substantially increased risk, with a 
white cell count more than 6 x 109 cells per L, haemoglobin less than or equal to 14.5 g/L, and 
CRP greater than or equal to 5 mg/L associated with risk of relapse on withdrawal of anti-TNF in 
Crohn’s disease.49,50 A model from the STORI trial,49 which incorporated these parameters, 
together with the additional variables of male sex, absence of surgical resection, and faecal 
calprotectin of 300 pg/g or greater, found that the presence of two or fewer risk factors was 
associated with a 15% relapse rate at 1 year. 
Faecal calprotectin might be elevated in the absence of endoscopic disease activity, and can help 
identify patients in deep remission, with concentrations of less than 56 pg/g predictive of stable 
remission in both ulcerative colitis and Crohn’s disease.63 In ulcerative colitis, a white cell count 
of more than 9.1x109 cells per L predicted relapse after withdrawal of azathioprine in one 
retrospective study,64 although this association has not been shown in other work. Evidence of 
mucosal healing at either imaging or endoscopy is associated with a reduced risk of relapse in 
patients with Crohn’s disease, with histological grade predictive in ulcerative colitis in a single 
study.60,52,65 
Importantly, up to 30% of patients with Crohn’s disease considered to be in deep remission with 
mucosal healing and low faecal calprotectin will still relapse, highlighting the importance of 
additional factors, such as the microbiome.66,67 A subanalysis of the STORI trial suggested that a 
low abundance of Faecalibacterium prausnitzii (adjusted HR 4.1 [95% CI 1.2-13.3]; p=0.014) 
and Bacteroides (3.3 [1.1-10.1]; p=0.030) predicted relapse following anti-TNF withdrawal 
independently of high CRP (p=0.0001).68 
A review of recent drug concentrations might also guide de-escalation decisions. Low or 
undetectable infliximab trough concentrations appear helpful in predicting a reduced risk of 
relapse when the drug is withdrawn.49,52 Most probably, this observation simply reflects that 
clinical remission has been achieved in the absence of a therapeutic dose of infliximab. The same 
is likely to be true for adalimumab concentration, but data are scarce. Conversely, for patients on 
combined infliximab and immunomodulator therapy, a higher infliximab trough concentration 
predicts a lower relapse rate when the immunomodulator is withdrawn.27 
Finally, of note, most of the predictive factors arise from retrospective studies, and thus a clear 
need exists for a well powered prospective study in this area. 
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STRATEGY TWO: DOSE DE-ESCALATION 
Dose reduction presents an alternative to complete drug withdrawal, providing cost savings and 
potentially reducing the risk of side-effects, although the reduction of side-effects has not yet 
been proven in patients with IBD. An increased risk of non-Hodgkin lymphoma was reported 
following higher doses of azathioprine in a large population of patients who had received a solid 
organ transplant, while higher concentrations of 6-TGN were associated with a higher risk of 
skin cancer in patients who had received renal transplants.69,70 Additionally, no data are 
available that prove a link between higher concentrations of biological agents and side-effects in 
IBD; however, an association between increasing drug concentration and increased risk of 
infection has been reported in patients with rheumatoid arthritis.71 
As previously outlined, one RCT has found that reduction of azathioprine, but not withdrawal, in 
patients receiving combination therapy, maintained similar median infliximab trough 
concentrations to continuation at full dose, supporting a dose de-escalation strategy.21 The 
TAXIT trial14 showed that monitoring of infliximab trough concentrations leads to more efficient 
dosing and allows safe dose reduction.14 At a single tertiary health-care centre, only 115 (44%) 
of263 patients with Crohn’s disease and ulcerative colitis who were clinically stable on 
infliximab maintenance therapy had optimal trough concentrations of 3-7 pg/mL and 
concentrations of more than 7 pg/mL were observed in 27% of the group.  
Importantly, patients randomly assigned to receive a dose regimen altered on the basis of serial 
monitoring of trough concentrations over a 1-year period had fewer flares than did those 
randomly assigned to be dosed on clinical criteria alone, although no difference in remission rate 
was noted. Two recent studies,72,73 further support the use of therapeutic drug monitoring to 
guide dose de-escalation. In a retrospective analysis of 91 patients with IBD receiving infliximab 
a trough concentration of more than 5-7 pg/mL before de-escalation and serial trough 
concentration of more than 2-4 pg/mL following de-escalation were associated with a lower risk 
of relapse.72 In a further retrospective study of 96 patients with IBD, dose de-escalation of 
infliximab if trough concentrations were more than 7 pg/mL was associated with a decreased 
risk of relapse (HR 0-45; p=0-024) compared with clinical de-escalation.73 
Lengthening of intervals between doses could also help achieve dose de-escalation. A 
retrospective study investigated the lengthening of dose intervals with adalimumab in patients 
with Crohn’s disease. Adalimumab was de-escalated from every other week to every 3 weeks in 
patients with trough adalimumab concentrations of more than 7 pg/mL or side-effects or both. 
26 (65%) of 40 patients remained in clinical remission with trough adalimumab concentrations 
of more than 4 pg/mL for a median follow-up of 24 months.74 Importantly, dose de-escalation 
was associated with the resolution of side-effects in half the patients. A CRP of less than 3-5 
mg/L at time of de-escalation was the only independent predictor of sustained remission. Dose 
de-escalation of adalimumab from every week to every other week was assessed in a separate 
retrospective study in Crohn’s disease, and was successful in 63% of patients.75 
STRATEGY THREE: EARLY DETECTION AND TREATMENT OF RELAPSE  
Careful objective monitoring for relapse is important following drug withdrawal because disease 
relapse might occur without clinical symptoms and both patients and health-care professionals 
might underestimate the relevance of mild symptoms.76 The risk of relapse is highest in the first 
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year following drug withdrawal; therefore, more intensive monitoring is appropriate.60 Despite 
substantial variability, secondary analysis of the STORI trial showed a higher median CRP 
concentration among patients who relapsed, with a concentration of more than 5 mg/L 
associated with a HR for relapse of 4-2 (95% CI 1-9-9-2; p<0-001).77 Serial monitoring of faecal 
calprotectin is also of value in predicting relapse following withdrawal of anti-TNF, based on 
data from a prospective multicentre study78 of patients with both Crohn’s disease and ulcerative 
colitis.78 Faecal calprotectin was found to increase up to 6 months before evidence of endoscopic 
relapse, with consistently low concentrations associated with sustained remission following 
drug withdrawal. Median concentrations consistently more than 120 pg/g were seen in patients 
who relapsed, which is substantially lower than the threshold of 250 pg/g reported as an 
independent predictor of relapse in the STORI trial (HR 6-5 [95% CI 2-7-15-6]; p<0-001), but 
this outcome might reflect the observation that baseline concentrations were also significantly 
higher in the STORI trial.49,77 
An important consideration following de-escalation is whether the patient’s response can be 
safely recaptured in the event of a relapse. In a multicentre UK study, reintroduction of 
thiopurine following a previous treatment regimen with thiopurine—lasting a median duration 
of 6 years—was successful in 31 (74%) of 42 patients with Crohn’s disease and in 22 (92%) of 
with ulcerative colitis.64 Two-thirds of patients with Crohn’s disease and half of those with 
ulcerative colitis also required systemic steroids to reinduce remission. It is notable that 25 
(86%) of 29 patients with Crohn’s disease and moderate-to-severe relapse within 12 months of 
azathioprine withdrawal required systemic steroids, anti-TNF, or hospital admission, with five 
of these patients requiring surgical resection. In an earlier study, remission was recaptured in 22 
(96%) of 23 patients with Crohn’s disease in an earlier study, although alternative therapy was 
chosen in nine (28%) of the 32 patients who initially relapsed following azathioprine 
withdrawal.31 Favourable proportions of patients who recaptured remission are also reported 
for anti-TNF therapy (table 4). A meta-analysis of retreatment with the same anti-TNF in 290 
patients with IBD found the rate of recapture of remission to be 80% (95% CI 68-91; 
p<0.00001), with response rates similar for both Crohn’s disease and ulcerative colitis.57 This 
rate is similar to that reported in two prospective studies, including the STORI trial.49,81 Higher 
early trough concentrations of infliximab upon reintroduction have been associated with long-
term response.82 Continued use of immunomodulators during the period of anti-TNF drug 
withdrawal in most patients is likely to protect against immunogenicity that would lead to loss 
of response and infusion reactions when the drug is reintroduced.60 
Data from 2017 suggest promising rates of recapture of response and a much lower risk of 
immunogenicity with vedolizumab.83 Interim analysis of the GEMINI longterm safety study83 
shows that remission rates improved from 9% to 48% at week 28 of retreatment for patients 
with Crohn’s disease who withdrew early from the GEMINI2 placebo maintenance phase 
because of relapse or non-medical reasons. 
Interest in the concept of drug holidays is growing, with the recognition that although therapies 
do not cure the underlying disease—meaning that relapse is common—the natural history of 
IBD is cyclical. Consequently, patients might experience long periods of remission after drug 
withdrawal once they have reached deep remission.17,49’84 Even transient drug withdrawal might 
be beneficial, reducing the total lifetime treatment burden and potentially reducing adverse 
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events and cost.47 In cases of borderline pharmacokinetics and low adherence with biological 
therapy, temporary drug cessation might also be less immunogenic.84As retreatment appears 
safe and effective in the majority of patients, this approach shows considerable promise and is 
the subject of ongoing research.46,49,57,85 
CLINICIAN AND PATIENT PERSPECTIVES TO DE-ESCALATION 
When considering de-escalation, the views of both the clinicians and the patients must be taken 
into account. Two surveys published in 201786 and 201887 are particularly illuminating with 
regard to this aspect of management. The first study, from the BIOCYCLE group,86 reported that 
gastroenterologists were significantly more likely to stop immunomodulator use (75% in 
Europe and 61% in the USA; p=0.05) than biological therapy (23% in Europe and 29% in the 
USA) for patients in with Crohn’s disease who are in remission. The risk of malignancy was 
regarded to be the most important reason for stopping immunomodulator therapy, with cost 
being the primary reason for stopping biological therapy. Importantly, there were clear cultural 
differences, with European gastroenterologists more likely than their US counterparts to 
recommend stopping combination therapy (44% in Europe vs 18% in the USA; p<0.05).86 
A second survey87 explored patient attitudes to de-escalation of combination therapy in Crohn’s 
disease in both France and the USA. Substantially more patients preferred to stop the 
immunomodulator regimen (53% in the USA vs 47% in France) than anti-TNF therapy (26% in 
the USA vs 28% in France). Importantly, 26% of all patients would not accept any de-escalation 
if the process increased the risk of an acute flare, and 56% of all patients were more concerned 
by Crohn’s disease activity than the risk of treatment-associated malignancy. Once again cultural 
differences were reported, with French patients more likely than US patients to consider 
stopping combination therapy if recommended by their clinician (69% in France vs 48% in the 
USA; p=0.04).87 
Current recommendations on the elective withdrawal of 
medical therapy for patients with IBD in remission 
In 2018, the European Crohn’s and Colitis Organisation (ECCO) published guidance on treatment 
withdrawal in IBD.60 The importance of individualising any withdrawal decision is emphasised, 
taking into account the views of the patient. When considering withdrawal of therapy, remission 
should be confirmed with a combination of clinical, biochemical, endoscopic, and imaging 
parameters, and predictors of relapse carefully considered. 
For immunomodulator monotherapy, the ECCO guidance suggests that the risks and benefits of 
continued treatment should be discussed after 3-4 years for those in established remission. 
When used in combination, withdrawal of the immunomodulator is considered unlikely to 
increase relapse rates in Crohn’s disease over the following 2 years, but this action might be 
inappropriate in patients with previously challenging disease or at high risk of unsuccessful 
biological treatment, including low infliximab trough concentrations. Anti-TNF withdrawal 
should typically only be considered in patients in deep remission, and maintenance 
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immunomodulator therapy might be appropriate to reduce risk of relapse. Anti-TNF 
discontinuation is not recommended in patients with perianal fistula given the high risk of 
relapse. Monitoring with serial faecal calprotectin and CRP is advised following treatment 
withdrawal, together with reassessment with imaging and endoscopy. More intensive 
monitoring is recommended in the first year after withdrawal of anti-TNF given the high relapse 
rates. In the UK, the National Institute for Health and Care Excellence recommends that patients 
with IBD on anti-TNF therapy should be reassessed at least annually, with a trial of treatment 
withdrawal considered if the patient is in stable remission, but no further specific guidance on 
patient selection or subsequent monitoring is provided.88,89 
A proposed withdrawal strategy 
The ECCO expert consensus provides valuable guidance for decision making.60 We agree that 
consideration of drug withdrawal should be made on a case-by-case basis and careful 
counselling of the patient is essential, including an explanation that the current predictors of 
outcome are not perfect. However, patients should also be reassured that they will be closely 
monitored following de-escalation, allowing early detection of relapse, and that clinical response 
will most likely be recaptured if therapy is restarted. Although the optimal frequency of 
monitoring has not been established, faecal calprotectin and CRP measurement every 3 months 
might be appropriate initially, allied with close observation of symptoms, recognising that the 
highest risk of relapse is in the first year. Following drug withdrawal any concern should prompt 
formal reassessment with endoscopy or imaging or both (figure). We emphasise the importance 
of carefully considering the consequences of relapse that might argue against de-escalation, even 
when risk of relapse is low. 
Future perspectives 
UNMET RESEARCH NEEDS 
Much of the data on drug de-escalation is from retrospective studies; therefore, high-quality 
RCTs are needed to guide decision making, several of which are underway. The standard-of-care 
for moderate-to-severe Crohn’s disease is combined therapy with an immunomodulator and 
biological therapy, but the SPARE study (NCT02177071), which forms part of the BIOCYCLE 
project, aims to definitively answer whether monotherapy is feasible. This multicentre European 
study will enrol 225 patients with Crohn’s disease in stable remission to one of three groups: 
continuation of both immunomodulator and biological, continuation of only immunomodulator, 
or continuation of only biological therapy. The efficacy of each treatment group to maintain 
remission will be assessed. Further data on the discontinuation of infliximab in Crohn’s disease 
will be provided by the STOP IT trial,90 while the BIOSTOP trial (EudraCT number 2016-001409-
18) will assess the effects of anti-TNF withdrawal in patients with ulcerative colitis and explore 
the feasibility of drug holidays, as the protocol allows for the anti-TNF to be restarted in the 
event of relapse.  
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Figure: An algorithm to guide decision making in drug de-escalation 
CDAI=Crohn's Disease Activity Index. CDEIS=Crohn's Disease Endoscopic Index of Severity. CRP=C-reactive protein. 
SES-CD=Simple Endoscopic Score for Crohn's Disease. SCAAI=Simple Clinical Colitis Activity Index. 
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PERSONALISATION OF APPROACH 
A core aim of the SPARE study is the identification of new biomarkers to predict the risk of 
relapse. This personalised approach to de-escalation of therapy is essential, as currently patients 
cannot be precisely stratified into appropriate treatment pathways. The use of molecular 
profiling to identify predictive biomarkers of disease course and treatment response is now of 
considerable research interest. In addition to HLA-DQA1*05, a number of other polymorphisms 
predict development of anti-drug antibodies, suggesting an additional benefit to determining a 
personalised gene expression signature for patients with IBD.35,91-93 Other genomics strategies 
are also under evaluation, including methylation, transcription, and protein glycosylation 
profiling. Additionally, the development of telemedicine systems promises closer monitoring of 
disease activity, and might enable earlier detection of relapse following treatment de-escalation 
in the future.94-97 
THE EFFECT OF EMERGING MEDICATIONS 
Novel therapies will probably substantially affect the clinician’s approach to drug withdrawal. 
No data are available for relapse rates following withdrawal of newer biologicals, like 
vedolizumab and ustekinumab, but the low risk of immunogenicity to these agents might 
simplify drug cycling. The emergence of small molecule inhibitors, such as the JAK inhibitors 
tofacitinib and filgotinib, is very relevant.98 These agents pose no risk of immunogenicity and act 
rapidly, with data suggesting that drug holidays are highly feasible. Data from the OCTAVE 
trials99 found that in patients who had previously responsed to tofacitinib, retreatment following 
a treatment interruption during the placebo phase of up to 44 weeks was effective in 75 (76%) 
of 99 patients at 2 months. 
Search strategy and selection criteria 
We searched the PubMed database to identify relevant manuscripts from inception until March 
31, 2019. The search combined the MeSH terms "inflammatory bowel disease", "Crohn’s disease" 
and "ulcerative colitis" with the subheadings "de-escalation", "therapy withdrawal", 
"immunomodulator withdrawal", "biologic withdrawal", "dose reduction", "therapeutic drug 
monitoring", "drug holiday", "risk of relapse", "cost saving", "lymphoma", "severe infection", 
"opportunistic infection", and "patient preference". We also reviewed bibliographies of the 
included studies to identify additional important data. We also assessed recent guidelines and 
topical reviews. Only papers published in English were reviewed, with priority given to 
randomised clinical trials and meta-analyses. 
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In summary, there remains much to learn about the appropriate and individualised de-
escalation of therapy in IBD. It is a highly important area in clinical practice, and worthy of 
greater research focus. With the emergence of stratified medicine, the next decade promises a 
potential transformation of both our understanding of IBD and the tools at our disposal, 
providing hope of greater precision in this challenging area of care 
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Definition of remission 
before de-escalation 
Definition of relapse Treatment 
group 
Relapse rate Time to 
relapse 
Notes 
6 months 12 months 18 months 24 months 






Clinical remission in 12 
months before enrolment, 
and CDAI <150 at baseline; 
>4years azathioprine 
Clinical relapse (CDAI >150 
with an increase of 60, new 
fistula development in a 
patient without fistula at 
enrolment; increase in PDAI by 
>4; hospitalisation for active 
Crohn's disease; oral steroids 


































Clinical remission (CDAI 
<150)and no need for 
medical or surgical 
treatment in previous 42 
months; >3-5 years 
azathioprine 
Clinical relapse 
(CDAI >250; CDAI 150-250 on 
3 consecutive weeks with an 
increase of 75; 
need for surgery for Crohn's 







































Clinical remission >2 years 
azathioprine Clinical relapse (CDAI >150, 












NA NA NA Not placebo 
controlled 
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Steroid free clinical 
remission and Baron 0-1 
>6 months azathioprine 








NA NA NA Results from the 
longterm 
remission 
patients: 61% for 
placebo vs 31% for 
azathioprine 
O'Donoghue 





Clinical remission >6 
months azathioprine 












NA NA NA Low dose steroids 
allowed in 
definition of stable 
disease 
RCT=randomised controlled trial. CDAI=Crohn's Disease Activity Index. PDAI=Perianal Disease Activity Index. NA=not applicable. Unless otherwise specified the duration of follow-up was 
the same at the duration of the RCT and is the same for all participants. *29 patients recruited, but only 28 completed the study or relapsed. 
 
 
Table2: Studies of immunomodulator withdrawal from combination therapy 
 Participants and 
duration of 
follow-up 
Definition of remission before 
de-escalation 
Definition of relapse Relapse rate Time to 
relapse 
Notes 
7 months 12 months 24 months 
Other 
timepoint 









Clinical or endoscopic 
remission >6 months (Crohn's 
disease: CDAI <150, faecal cal 
protectin n <250 pg/g; 
ulcerative colitis: Mayo score 
< 3, endoscopic subscore 0-1, 
and stool subscore 0); >1year 
infliximab and azathioprine 
Clinical relapse and any 










NA NA NS Dose reduction but 
not discontinuation 
appeared to be as 
effective as 
continuation of 
azathioprine at full 
dose, but not 
statistically 
significant 
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Clinical remission >5-4 
months; >4 months infliximab 
and immunomodulators 
Clinical relapse and the 





NA NA NA At end of 
follow-up 72-





No difference was 
found between those 
who stopped or de-
escalated therapy in 
terms of the length of 







Clinical remission >4 months 
(PCDAI <30 and PCDAI drop 
>15 since infliximab started); 
>6.5 months infliximab and 
azathioprine 
Clinical relapse or loss of 
response to anti -TN F 
35.9% for the 
discontinuation 
group; 33.3% for 
the continuation 
group 
NA NA NA NS High risk of bias: no 
placebo and no 
blinding 









Clinical remission >6 months 
infliximab and azathioprine 
Clinical relapse requiring 
a change of treatment, 
unsuccessful inflixiab 
regimen, or colectomy 



























Clinical and biochemical 
remission >6 months (low 
CRP [<10 mg/L], persistent 
improvement of IBD 
symptoms) >6-5 months 
infliximab and 
immunomodulators 
Clinical and biochemical 
relapse 
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Controlled disease for 2 
months infliximab, NS 
azathioprine 
Recurrence requiring 
steroids or surgery 
NA 42.8% for the 
discontinuation 
group; 40% for 
the continuation 
group 










Clinical remission (CDAI 
<150); >6 months infliximab 
and azathioprine 
Infliximab failure, 
intensification of dosing 
or switch to adalimumab, 
infliximab intolerance, or 
major surgery 
NA 15% for the 
discontinuation 
group 
59% for the 
discontinuation 
group 













infliximab failure on 
azathioprine 
withdrawal 
Sokol et al 
(2009)28; 
retrospectiv
e (abstract) IBD (N=118); 
NS 
Controlled disease duration 
before drug therapy N S 
Intensification of 
infliximab dosing 
NA 38'8% for the 
discontinuation 
group; 40'6% for 
the continuation 
group 








Clinical remission (absence of 
intestinal or extra-intestinal 
symptoms); >6 months 
infliximab and 
immunomodulators 
Clinical relapse (CDAI 
increase by >70 leading 
to change in infliximab 
dosing or infliximab 
stopped for any reason) 
NA NA 55% for the 
discontinuation 




NA NS No placebo and no 
blinding 
RCT=randomised controlled trial. IBD=inflammatory bowel disease. CDAI=Crohn’s Disease Activity Index. NA=not applicable. NS=not specified . CRP=C-reactive protein. 




Table 3: Studies of withdrawal of biological therapy 
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6 months 12 months 24 months 

















Bradshaw Index ≤4; 
perianal Crohn's 
disease: absence of 
fistula drainage 
ulcerative colitis: 
partial Mayo score 
≤2) duration before 














24% 38% 46% relapse 
at 3 years; 






The IBD subtype was not 
associated with risk of 
relapse; in patients classified 
as being in deep remission, 
the rate of re lapse was still 
similar (22% for Crohn's 
disease and 20% for 
ulcerative colitis after 1 
year) 



















so called infliximab 
failure 












Two-thirds of patients were 
successfully deescalated, a 
fifth of patients never 
restarted biological therapy 












IBD: 66% with 
Crohn's disease 
and 75% with 
ulcerative 
colitis 
Steroid free clinical 
remission >6 
months, >12 months 
anti- TN F with or 
without 
immunomodulators 


























NS Approximately a third of 
patients with IBD flared 
within 12 months of 
withdrawal of anti- TNF 
Published in : The lancet. Gastroenterology & Hepatology (2020) 
DOI: 10.1016/S2468-1253(19)30186-4 














84% Clinical remission 
(PGA); with median 
infliximab 73 months 
(IQR 1.4-16.2 
months) 





need for thiopurine 












2% at 5 years, 
and 48% at 
end of follow-
up 
NS Lowest rates of relapse 
reported; many patients 
included were treated 
episodically 












IBD: 41% with 
Crohn's disease 








CDAI rise of >100 
and CDAI >150; 
ulcerative colitis: 
partial Mayo >3) 























81% Clinical remission 
(Crohn's disease: 
CDAI <150 ulcerative 
colitis: Mayo <2) 
>12 months 
infliximab or 




CDAI rise of >100 
and 
CDAI >150 points 
ulcerative colitis: 
partial Mayo >3) 





NA NA NS Relapse rate combined for 
ulcerative colitis and Crohn's 
disease 
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384 months for 
the maintenance 
group; median 55 
months for the 
induction group 
100% Clinical remission 
(Harvey- Brad shaw 
Index <4): 
maintenance group 
≥1 year infliximab 
and immuno-
modulators; 
induction group >8 
weeks infliximab and 
immunomodulators 





















Compared relapse rate after 
two different infliximab 
treatment strategies: 
induction or maintenance for 
at least 1 year 






83'6% Clinical remission 
(CDAI <150) 
>52 weeks infliximab 




(CDAI rise >100 






NA NA Median time 
6 months 
Biological therapy was 
restarted a median of 6 
months after anti- TNF 
discontinuation in almost 
half of patients with Crohn's 
disease 














(CDAI >250 or 
CDAI 150-250 with 
>70 rise from 













NA Median time 
16-4 months 
Approximately a half of 
patients with Crohn's 
disease treated with at least 
1 year of combination 
therapy relapsed within 1 
year of anti-TNF withdrawal 
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Clinical relapse (PGA 
and steroid-free 
stable disease, no 
fistula secretion or 










steroid, or surgery 















IBD=inflammatory bowel disease. CDAI=Crohn's Disease Activity Index. PGA=patient global assessment. NA=not applicable. NS=not specified. Unless otherwise specified the 
duration of follow-up was the same at the duration of the RCT and is the same for all participants. 
 
Table 4: Studies of re-treatment with anti-TN F agents 









Achieved remission and the time to 
remission (%) 
Adverse effects Notes 











Median of 11 months 78% 67% clinical remission at 14 weeks 
and 75% in clinical remission and 
13% partial response at end of 




3% of patients who relapsed went to surgery; 
similar results were found in patients in deep 
remission: 78% in clinical remission and 15% 
partial response at end of follow-up 








Median of 13 months 71% 66% of those without infliximab 
restart failure (no acute or delayed 
infusion reaction, non-response, 
loss of response, or infliximab-
NS 18 patients had major complications a median of 
50 months after stopping infliximab; 22 did not 
restart infliximab or need another biological 
(follow-up 
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related sideeffects); timepoint NS 78 months) 
Kennedy et al 
(2016)46; 
retrospective 
IBD (N=166; Crohn's 
disease [n=146] and 



















93% successful in those with 
Crohn's disease and 67% successful 
of those with ulcerative colitis; 
timepoint NS 
NS 40% of patients with Crohn's disease needed 
steroids and 4% surgery 
Monterubbian





66% NS 52% 633% clinical remission; time point 
NS 
Loss of response in 
27% and infusion 
reaction in 10% 
NA 
Dai et al 
(2014)53; 
prospective 
IBD (N=218; Crohn's 
disease [n=109]; 











Median of 4’8 months 
for those with 
Crohn's disease; 
median of 6-7 
months for those 
with ulcerative colitis 
100% for 
both groups 
783% clinical response (mean 3 
months) in those with Crohn's 
disease; 667% clinical response 
(mean 3 months) in those with 
ulcerative colitis 
NS NA 
Farkas et al 
(2014)54; 
prospective 
IBD (N =47; Crohn's 
disease [n=35 ]; 
ulcerative colitis 
[n=12]) 
81% NS NS 81% clinical response in those with 
Crohn's disease; 54% clinical 
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100% Median of 327 
months for the 
induction group; 
median of 15-9 
months for the 
maintenance group 
80% 89% clinical remission, 72% 
remained in steroid-free remission 
(median l.2years[IQR 0.3-2.4]) 
NS NA 





80% Mean of 7-5 months 86% 93% initial response and 92% in 





Molander et al 
(2014)44; 
prospective 
IBD (N=52; Crohn's 
disease [n=17]; 









NS 88% 93% in clinical remission (3 
months); 90% clinical remission 
(12 months) for both groups of 
patients 








83.6% Median of 6 months 100% 547% clinical remission Mild side-effects in 
4% and infusion 
reaction in 6% 
NA 





100% Median of 16.4 
months 
100% Before third infliximab infusion: 
88% (38/43) clinical remission and 
98% (42/43) clinical response 
NS NA 
IBD=inflammatory bowel disease. NS=not specified. NA=not applicable. 
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